Identification

Name
Betamethasone
Accession Number
DB00443  (APRD00513)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)

Structure
Thumb
Synonyms
  • 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione
  • 16β-Methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione
  • 9-Fluoro-16beta-methylprednisolone
  • 9-Fluoro-16β-methylprednisolone
  • 9alpha-Fluoro-16beta-methylprednisolone
  • 9α-Fluoro-16β-methylprednisolone
  • beta-Methasone alcohol
  • Betadexamethasone
  • Betametasona
  • Betamethasone
  • Betamethasonum
  • Betamethasonvalerat Mikron
  • Rinderon
External IDs
NSC-39470 / SCH 4831 / SCH-4831
Product Ingredients
IngredientUNIICASInChI Key
Betamethasone acetateTI05AO53L7987-24-6AKUJBENLRBOFTD-QZIXMDIESA-N
Betamethasone benzoate877K0XW47A22298-29-9SOQJPQZCPBDOMF-YCUXZELOSA-N
Betamethasone dihydrogen phosphateYJO1F9W10R360-63-4VQODGRNSFPNSQE-DVTGEIKXSA-N
Betamethasone dipropionate826Y60901U5593-20-4CIWBQSYVNNPZIQ-XYWKZLDCSA-N
Betamethasone sodium phosphate7BK02SCL3W151-73-5PLCQGRYPOISRTQ-LWCNAHDDSA-L
Betamethasone valerate9IFA5XM7R22152-44-5SNHRLVCMMWUAJD-SUYDQAKGSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Beben Gel 0.025%Gel0.025 %TopicalParke Davis Division, Warner Lambert Canada Inc.1973-12-311999-04-08Canada
Betacort Scalp Lotion 0.1%Liquid.1 %TopicalIcn Pharmaceuticals1981-12-312005-04-26Canada
Betaderm Crm 0.05%Cream0.05 %TopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Betaderm Crm 0.1%Cream0.1 %TopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Betaderm Lotion 0.1%Lotion0.1 %TopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Betaderm Ont 0.05%Ointment0.05 %TopicalTaro Pharmaceuticals, Inc.1979-12-31Not applicableCanada
Betaderm Ont 0.1%Ointment0.1 %TopicalTaro Pharmaceuticals, Inc.1988-12-31Not applicableCanada
Betagel - 0.1%Gel.1 %TopicalUcb Inc1996-12-061998-04-21Canada
Betamethasone DipropionateOintment.5 mg/gTopicalA S Medication Solutions1984-09-04Not applicableUs
Betamethasone DipropionateCream.5 mg/gTopicalA S Medication Solutions1984-06-262017-06-20Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BetamethasoneCream.5 mg/gTopicalImpax Generics2004-01-232017-10-17Us
Betamethasone DipropionateLotion.5 mg/gTopicalPerrigo New York Inc.2006-06-30Not applicableUs
Betamethasone DipropionateCream.5 mg/gTopicalPhysicians Total Care, Inc.2011-09-06Not applicableUs
Betamethasone DipropionateCream.5 mg/gTopicalActavis Pharma Company2002-09-03Not applicableUs
Betamethasone DipropionateCream.5 mg/gTopicalH.J. Harkins Company1984-02-26Not applicableUs
Betamethasone DipropionateCream.5 mg/gTopicalA S Medication Solutions2008-09-232017-06-20Us
Betamethasone DipropionateLotion.5 mg/mLTopicalVersa Pharm, Inc. An Akorn Company2018-05-01Not applicableUs
Betamethasone DipropionateLotion.5 mg/mLTopicalGw Pharmaceuticals Ltd.2016-09-05Not applicableUs
Betamethasone DipropionateCream.5 mg/gTopicalA S Medication Solutions2006-09-282017-06-20Us
Betamethasone DipropionateGel.5 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2003-05-13Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Beta 1 KitBetamethasone acetate (3 mg/1mL) + Betamethasone sodium phosphate (3 mg/1mL)KitIntra-articular; Intralesional; IntramuscularOaklock, Llc2015-08-25Not applicableUs
Beta 1 KitBetamethasone acetate (3 mg/1mL) + Betamethasone sodium phosphate (3 mg/1mL)KitIntra-articular; Intralesional; IntramuscularOaklock, Llc2015-08-25Not applicableUs
BetajectBetamethasone (3 mg) + Betamethasone acetate (3 mg)SuspensionIntra-articular; Intralesional; IntramuscularSandoz Canada Incorporated1998-07-02Not applicableCanada
BetajectBetamethasone (3 mg) + Betamethasone acetate (3 mg)SuspensionIntra-articular; Intralesional; IntramuscularSandoz Canada Incorporated1998-07-02Not applicableCanada
Betamethasone ClotrimazoleBetamethasone dipropionate (.64 mg/1) + Clotrimazole (10 mg/1)CreamTopicalStat Rx USA2002-08-022018-02-08Us
Betamethasone Sodium Phosphate and Betamethasone AcetateBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (3 mg/mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularPharma Force, Inc.2009-07-31Not applicableUs
Betamethasone Sodium Phosphate and Betamethasone AcetateBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (3 mg/mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularAmerican Regent2010-04-28Not applicableUs
Betamethasone Sodium Phosphate and Betamethasone AcetateBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (3 mg/mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularRemedy Repack2017-05-09Not applicableUs
Betamethasone Sodium Phosphate and Betamethasone AcetateBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (3 mg/mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularRemedy Repack2017-05-09Not applicableUs
Betamethasone Sodium Phosphate and Betamethasone AcetateBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (3 mg/mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularPharma Force, Inc.2009-07-31Not applicableUs
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Betaloan SUIKBetamethasone sodium phosphate (3 mg/mL) + Betamethasone acetate (3 mg/mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularAsclemed Usa, Inc.2010-04-28Not applicableUs
Betaloan SUIKBetamethasone sodium phosphate (3 mg/mL) + Betamethasone acetate (3 mg/mL)Injection, suspensionIntra-articular; Intralesional; IntramuscularAsclemed Usa, Inc.2010-04-28Not applicableUs
Betamethasone Combo 6mg/mL PFBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (3 mg/mL)Injection, suspensionEpidural; Intramuscular; Intraspinal; IntrathecalUs Compounding, Inc2013-12-202015-12-29Us
Betamethasone Combo 6mg/mL PFBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (3 mg/mL)Injection, suspensionEpidural; Intramuscular; Intraspinal; IntrathecalUs Compounding, Inc2013-12-202015-12-29Us
Betamethasone Combo 7mg/mLBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (4 mg/mL)Injection, suspensionIntramuscularUs Compounding, Inc2013-12-202015-12-29Us
Betamethasone Combo 7mg/mLBetamethasone acetate (3 mg/mL) + Betamethasone sodium phosphate (4 mg/mL)Injection, suspensionIntramuscularUs Compounding, Inc2013-12-202015-12-29Us
Betamethasone SP 24mg/2mL PFBetamethasone sodium phosphate (12 mg/mL)Injection, solutionEpidural; Intramuscular; Intraspinal; IntrathecalUs Compounding, Inc2013-12-202015-12-29Us
Dr. Throwers BetaBetamethasone dipropionate (.05 g/100g)CreamTopicalDr. Thrower's Skincare, Inc.2015-05-15Not applicableUs
Dr. Throwers BetaBetamethasone (.05 g/100g)OintmentTopicalDr. Thrower's Skincare, Inc.2015-05-15Not applicableUs
Dr. Throwers Pbc No. 1Betamethasone dipropionate (.5 g/100g) + Hydroquinone (12 g/100g) + Tretinoin (.1 g/100g)CreamTopicalDr. Thrower's Skincare, Inc.2015-05-15Not applicableUs
International/Other Brands
Bentelan (Defiante) / Betnovate (GlaxoSmithKline) / Celestamine (Schering-Plough) / Celestone (Schering-Plough) / Diprosone (Schering-Plough) / Fucibet (LEO) / Procort / Rinderon (Shionogi Seiyaku)
Categories
UNII
9842X06Q6M
CAS number
378-44-9
Weight
Average: 392.4611
Monoisotopic: 392.199902243
Chemical Formula
C22H29FO5
InChI Key
UREBDLICKHMUKA-DVTGEIKXSA-N
InChI
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,17-,19-,20-,21-,22-/m0/s1
IUPAC Name
(1R,2S,10S,11S,13S,14R,15S,17S)-1-fluoro-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12C[C@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Pharmacology

Indication

Topical use (cream, lotion and ointment): for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Topical use (foam): relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Systemic use: for the treatment of edocrine disorders, rheumatic disorders, collagen diseases, dermatological diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, tuberculous meningitis and trichinosis.

Associated Conditions
Pharmacodynamics

Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections.

Mechanism of action

Betamethasone is a glucocorticoid receptor agonist. This leads to changes in genetic expression once this complex binds to the GRE. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Minimal if applied topically.

Volume of distribution
Not Available
Protein binding

64%

Metabolism

Hepatic

Route of elimination
Not Available
Half life

5.6 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Betamethasone.Experimental
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Betamethasone.Investigational
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Betamethasone is combined with 1,10-Phenanthroline.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Betamethasone.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Betamethasone.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Betamethasone.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Betamethasone.Approved, Experimental, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Betamethasone is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Betamethasone.Approved, Investigational, Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Betamethasone.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Betamethasone.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Betamethasone.Experimental, Investigational
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Betamethasone.Approved, Withdrawn
AldesleukinBetamethasone may decrease the antineoplastic activities of Aldesleukin.Approved
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Betamethasone.Investigational
AlmasilateThe bioavailability of Betamethasone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Betamethasone.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Betamethasone.Approved
AloglutamolThe bioavailability of Betamethasone can be decreased when combined with Aloglutamol.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Betamethasone.Experimental
AluminiumThe bioavailability of Betamethasone can be decreased when combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe bioavailability of Betamethasone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Betamethasone can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Betamethasone can be decreased when combined with Aluminum hydroxide.Approved, Investigational
AmbenoniumThe risk or severity of adverse effects can be increased when Betamethasone is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Betamethasone.Approved
AmiodaroneThe serum concentration of Betamethasone can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BBetamethasone may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Betamethasone.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Betamethasone.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Betamethasone is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Betamethasone.Approved, Investigational
AntrafenineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Betamethasone can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Betamethasone.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Betamethasone.Approved, Investigational
AprepitantThe serum concentration of Betamethasone can be increased when it is combined with Aprepitant.Approved, Investigational
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Betamethasone.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Betamethasone can be increased when it is combined with Atazanavir.Approved, Investigational
AtorvastatinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Atorvastatin.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Betamethasone.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Betamethasone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Betamethasone.Approved
AzosemideBetamethasone may increase the hypokalemic activities of Azosemide.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Betamethasone is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Betamethasone is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Betamethasone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Betamethasone.Approved, Investigational
BazedoxifeneThe serum concentration of Betamethasone can be increased when it is combined with Bazedoxifene.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Betamethasone.Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Betamethasone.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Betamethasone.Experimental
BendroflumethiazideBetamethasone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Betamethasone.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Betamethasone.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Betamethasone.Approved, Investigational
BenzthiazideBetamethasone may increase the hypokalemic activities of Benzthiazide.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Betamethasone.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Betamethasone.Experimental
Bismuth SubcitrateThe bioavailability of Betamethasone can be decreased when combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe bioavailability of Betamethasone can be decreased when combined with Bismuth subnitrate.Approved
BoceprevirThe serum concentration of Betamethasone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Betamethasone.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Betamethasone.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Betamethasone.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Betamethasone.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Betamethasone.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Betamethasone.Investigational, Withdrawn
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Betamethasone.Experimental
BumetanideBetamethasone may increase the hypokalemic activities of Bumetanide.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Betamethasone.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Betamethasone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Betamethasone can be decreased when combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe bioavailability of Betamethasone can be decreased when combined with Calcium silicate.Experimental
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Betamethasone.Approved
Capromab pendetideBetamethasone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CapsaicinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Capsaicin.Approved
CarbamazepineThe serum concentration of Betamethasone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Betamethasone.Experimental, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Betamethasone.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Betamethasone.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Betamethasone.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Betamethasone.Approved, Investigational
CeritinibBetamethasone may increase the hyperglycemic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Betamethasone.Approved, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Betamethasone.Approved, Investigational, Vet Approved
ChlorothiazideBetamethasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Betamethasone can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Betamethasone.Approved, Investigational
ChlorthalidoneBetamethasone may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Betamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Betamethasone.Approved
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Betamethasone.Experimental
CimicoxibThe risk or severity of adverse effects can be increased when Betamethasone is combined with Cimicoxib.Investigational
CinoxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Cisplatin.Approved
ClarithromycinThe serum concentration of Betamethasone can be increased when it is combined with Clarithromycin.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Betamethasone is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Betamethasone.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Betamethasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Betamethasone can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Betamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Betamethasone resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Betamethasone can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Betamethasone.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Betamethasone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Betamethasone is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Betamethasone.Approved, Investigational
CyclopenthiazideBetamethasone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
DaidzeinThe serum concentration of Betamethasone can be increased when it is combined with Daidzein.Experimental
DanazolBetamethasone may increase the fluid retaining activities of Danazol.Approved
DarunavirThe serum concentration of Betamethasone can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Betamethasone is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Betamethasone is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Betamethasone is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Betamethasone.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Betamethasone.Investigational
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Betamethasone.Investigational
DexibuprofenThe risk or severity of adverse effects can be increased when Betamethasone is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Betamethasone is combined with Dexketoprofen.Approved, Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Betamethasone is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Betamethasone.Approved, Vet Approved
DienestrolThe serum concentration of Betamethasone can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Betamethasone can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Betamethasone.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Betamethasone.Approved, Investigational
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Betamethasone.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Betamethasone.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Betamethasone.Experimental
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Betamethasone.Approved, Investigational
DipivefrinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Dipivefrin.Approved
DistigmineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Betamethasone is combined with Donepezil.Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Betamethasone.Withdrawn
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Betamethasone.Approved, Investigational
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Betamethasone.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Betamethasone.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Betamethasone is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Betamethasone is combined with Edrophonium.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Betamethasone.Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Betamethasone.Experimental
EnoxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Betamethasone can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Betamethasone can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Betamethasone.Approved
EpitizideBetamethasone may increase the hypokalemic activities of Epitizide.Experimental
EquolThe serum concentration of Betamethasone can be increased when it is combined with Equol.Investigational
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Betamethasone.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Betamethasone.Approved
EstradiolThe serum concentration of Betamethasone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Betamethasone can be increased when it is combined with Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Betamethasone can be increased when it is combined with Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Betamethasone can be increased when it is combined with Estradiol valerate.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Betamethasone can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedThe serum concentration of Betamethasone can be increased when it is combined with Estrogens, esterified.Approved
EstroneThe serum concentration of Betamethasone can be increased when it is combined with Estrone.Approved
Etacrynic acidBetamethasone may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Betamethasone.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Betamethasone.Experimental
Ethinyl EstradiolThe serum concentration of Betamethasone can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Betamethasone.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Betamethasone.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Betamethasone.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Betamethasone.Investigational, Nutraceutical
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Betamethasone.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Betamethasone.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Betamethasone.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Betamethasone.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Betamethasone.Approved
FenthionThe risk or severity of adverse effects can be increased when Betamethasone is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Betamethasone.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Betamethasone.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Betamethasone.Experimental
FingolimodBetamethasone may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Betamethasone is combined with Fish oil.Approved, Nutraceutical
FleroxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Betamethasone.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Betamethasone.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Betamethasone.Experimental
FluoxymesteroneBetamethasone may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Betamethasone.Approved, Investigational
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Betamethasone.Approved
FosaprepitantThe serum concentration of Betamethasone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Betamethasone can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FurosemideBetamethasone may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Betamethasone is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Betamethasone is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Betamethasone can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Betamethasone is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Betamethasone is combined with Ginkgo biloba.Approved, Investigational, Nutraceutical
GinsengThe risk or severity of adverse effects can be increased when Betamethasone is combined with Ginseng.Approved, Investigational, Nutraceutical
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Betamethasone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Betamethasone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Betamethasone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Betamethasone.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Betamethasone.Approved, Investigational
GLPG-0492Betamethasone may increase the fluid retaining activities of GLPG-0492.Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Betamethasone.Approved
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Betamethasone.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Betamethasone.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Betamethasone.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Betamethasone.Experimental
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Betamethasone is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HexestrolThe serum concentration of Betamethasone can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Betamethasone.Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Human rabies virus immune globulin.Approved
Huperzine AThe risk or severity of adverse effects can be increased when Betamethasone is combined with Huperzine A.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Betamethasone.Approved, Investigational
HydrochlorothiazideBetamethasone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideBetamethasone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Betamethasone can be decreased when combined with Hydrotalcite.Approved, Experimental, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Betamethasone.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Betamethasone.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Betamethasone.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Betamethasone.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Betamethasone is combined with Icosapent.Approved, Nutraceutical
IdelalisibThe serum concentration of Betamethasone can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Betamethasone.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Betamethasone.Approved
IndapamideBetamethasone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Betamethasone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Betamethasone.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Betamethasone.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Betamethasone.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Betamethasone is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Betamethasone is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Betamethasone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Betamethasone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Betamethasone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Betamethasone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Betamethasone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Betamethasone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Betamethasone.Approved
IpidacrineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Ipidacrine.Experimental
IsavuconazoleThe serum concentration of Betamethasone can be increased when it is combined with Isavuconazole.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Betamethasone is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Betamethasone.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Betamethasone.Withdrawn
ItraconazoleThe serum concentration of Betamethasone can be increased when it is combined with Itraconazole.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Betamethasone is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Betamethasone.Experimental
KetoconazoleThe serum concentration of Betamethasone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Betamethasone.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Betamethasone.Approved
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Betamethasone.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Betamethasone is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Levofloxacin.Approved, Investigational
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Betamethasone.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Betamethasone.Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Betamethasone.Investigational
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Betamethasone.Approved, Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Betamethasone.Experimental
LopinavirThe serum concentration of Betamethasone can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Betamethasone.Approved, Investigational
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Betamethasone.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Betamethasone.Approved, Investigational
LumacaftorThe serum concentration of Betamethasone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Betamethasone.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Betamethasone.Illicit, Investigational, Withdrawn
MagaldrateThe bioavailability of Betamethasone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateThe bioavailability of Betamethasone can be decreased when combined with Magnesium carbonate.Approved, Investigational
Magnesium hydroxideThe bioavailability of Betamethasone can be decreased when combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe bioavailability of Betamethasone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Betamethasone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Betamethasone.Approved
Magnesium silicateThe bioavailability of Betamethasone can be decreased when combined with Magnesium silicate.Approved
Magnesium TrisilicateThe bioavailability of Betamethasone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Betamethasone is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Betamethasone.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Betamethasone.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Betamethasone.Approved
MefloquineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Mefloquine.Approved, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Betamethasone.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Betamethasone.Approved
MesteroloneBetamethasone may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Betamethasone can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Betamethasone.Approved, Investigational, Withdrawn
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Betamethasone.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Betamethasone.Approved
MethallenestrilThe serum concentration of Betamethasone can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Betamethasone is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideBetamethasone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Betamethasone.Approved, Vet Approved
MethylergometrineThe risk or severity of adverse effects can be increased when Methylergometrine is combined with Betamethasone.Approved
MethyltestosteroneBetamethasone may increase the fluid retaining activities of Methyltestosterone.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Betamethasone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Betamethasone is combined with Metoclopramide.Approved, Investigational
MetolazoneBetamethasone may increase the hypokalemic activities of Metolazone.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Betamethasone.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Betamethasone.Approved, Experimental
MifepristoneThe therapeutic efficacy of Betamethasone can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Betamethasone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Betamethasone.Approved
MinaprineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Betamethasone.Approved, Investigational
MitotaneThe serum concentration of Betamethasone can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Betamethasone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Betamethasone.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Betamethasone.Experimental
MorniflumateThe risk or severity of adverse effects can be increased when Betamethasone is combined with Morniflumate.Approved
MoxestrolThe serum concentration of Betamethasone can be increased when it is combined with Moxestrol.Experimental
MoxifloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Betamethasone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Betamethasone.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Betamethasone.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Betamethasone.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Betamethasone.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Betamethasone is combined with Nalidixic Acid.Approved, Investigational
NandroloneBetamethasone may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
Nandrolone decanoateBetamethasone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Illicit
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Betamethasone.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Betamethasone is combined with Natalizumab.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Betamethasone.Approved, Investigational
NefazodoneThe serum concentration of Betamethasone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Betamethasone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Betamethasone.Approved, Investigational
NevirapineThe serum concentration of Betamethasone can be decreased when it is combined with Nevirapine.Approved
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Betamethasone.Approved, Investigational
NicorandilThe risk or severity of adverse effects can be increased when Betamethasone is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Betamethasone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Betamethasone.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Betamethasone.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Betamethasone.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Norfloxacin.Approved
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Betamethasone.Approved, Investigational
OfloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Ofloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Betamethasone.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Betamethasone.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Betamethasone.Vet Approved
OxandroloneBetamethasone may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Betamethasone.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Betamethasone is combined with Oxolinic acid.Experimental
OxymetholoneBetamethasone may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Betamethasone.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Betamethasone.Experimental, Nutraceutical
ParaoxonThe risk or severity of adverse effects can be increased when Betamethasone is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Betamethasone.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Betamethasone.Approved, Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Betamethasone can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Betamethasone.Approved, Investigational, Vet Approved, Withdrawn
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Betamethasone.Approved, Investigational, Withdrawn
PhenobarbitalThe serum concentration of Betamethasone can be decreased when it is combined with Phenobarbital.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Betamethasone.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Betamethasone.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Betamethasone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Betamethasone.Approved, Investigational
PhenytoinThe serum concentration of Betamethasone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Physostigmine.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Betamethasone.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Betamethasone.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Betamethasone is combined with Pipemidic acid.Experimental
PiretanideBetamethasone may increase the hypokalemic activities of Piretanide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Betamethasone.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Betamethasone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Betamethasone.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Betamethasone.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Betamethasone.Approved
PitolisantThe serum concentration of Betamethasone can be decreased when it is combined with Pitolisant.Approved, Investigational
Polyestradiol phosphateThe serum concentration of Betamethasone can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideBetamethasone may increase the hypokalemic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Betamethasone is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Betamethasone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Betamethasone.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Betamethasone.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Betamethasone.Approved
PrimidoneThe serum concentration of Betamethasone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Betamethasone.Experimental
PromestrieneThe serum concentration of Betamethasone can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Betamethasone.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Betamethasone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Betamethasone.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Betamethasone.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Pyridostigmine.Approved, Investigational
QuinestrolThe serum concentration of Betamethasone can be increased when it is combined with Quinestrol.Approved
QuinethazoneBetamethasone may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Betamethasone.Approved, Investigational
RanolazineThe serum concentration of Betamethasone can be increased when it is combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Betamethasone.Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Betamethasone.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Betamethasone.Approved, Experimental, Investigational
RifabutinThe serum concentration of Betamethasone can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Betamethasone can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Betamethasone can be decreased when it is combined with Rifapentine.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Betamethasone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rindopepimut.Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Betamethasone.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Betamethasone.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Betamethasone.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rosoxacin.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Betamethasone.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rubella virus vaccine.Approved, Investigational
RufloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Betamethasone.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Betamethasone.Approved, Investigational, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Betamethasone is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Betamethasone is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Betamethasone.Approved
SaquinavirThe serum concentration of Betamethasone can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Betamethasone.Approved
SecoisolariciresinolThe serum concentration of Betamethasone can be increased when it is combined with Secoisolariciresinol.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Betamethasone is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Betamethasone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Betamethasone.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Betamethasone.Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Betamethasone.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Betamethasone.Approved, Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Sitafloxacin.Experimental, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Betamethasone.Approved, Investigational
Sodium bicarbonateThe bioavailability of Betamethasone can be decreased when combined with Sodium bicarbonate.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Betamethasone.Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Betamethasone is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Betamethasone.Investigational
St. John's WortThe serum concentration of Betamethasone can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneBetamethasone may increase the fluid retaining activities of Stanolone.Illicit, Investigational
StanozololBetamethasone may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Betamethasone can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Betamethasone.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Betamethasone.Approved, Investigational
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Betamethasone.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Betamethasone.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Betamethasone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Betamethasone can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Betamethasone can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Tacrine.Investigational, Withdrawn
TacrolimusTacrolimus may increase the immunosuppressive activities of Betamethasone.Approved, Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Betamethasone is combined with Talniflumate.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Betamethasone.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Betamethasone is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Betamethasone.Approved, Withdrawn
TelithromycinThe serum concentration of Betamethasone can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Betamethasone.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Betamethasone.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Betamethasone.Vet Approved
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Betamethasone.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Betamethasone.Approved
TestosteroneBetamethasone may increase the fluid retaining activities of Testosterone.Approved, Investigational
Testosterone cypionateThe risk or severity of edema formation can be increased when Testosterone cypionate is combined with Betamethasone.Approved
Testosterone enanthateThe risk or severity of edema formation can be increased when Testosterone enanthate is combined with Betamethasone.Approved
Testosterone propionateBetamethasone may increase the fluid retaining activities of Testosterone propionate.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe risk or severity of fluid retention can be increased when Testosterone undecanoate is combined with Betamethasone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Betamethasone is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Betamethasone.Approved
TiboloneThe serum concentration of Betamethasone can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Betamethasone.Investigational
TofacitinibBetamethasone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Betamethasone.Approved, Investigational
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Betamethasone.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Betamethasone.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Betamethasone.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Betamethasone.Approved
TorasemideBetamethasone may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Betamethasone.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Betamethasone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Triamcinolone.Approved, Vet Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Betamethasone.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Betamethasone is combined with Trichlorfon.Vet Approved
TrichlormethiazideBetamethasone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Betamethasone.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Betamethasone.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Betamethasone.Approved
TromethamineThe bioavailability of Betamethasone can be decreased when combined with Tromethamine.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Tubocurarine.Approved
Typhoid VaccineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Typhoid Vaccine.Approved
TyrothricinThe risk or severity of adverse effects can be increased when Betamethasone is combined with Tyrothricin.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Betamethasone.Approved, Investigational, Withdrawn
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Betamethasone is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VemurafenibThe serum concentration of Betamethasone can be increased when it is combined with Vemurafenib.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Betamethasone.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Betamethasone.Approved, Investigational
VoriconazoleThe serum concentration of Betamethasone can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinBetamethasone may increase the anticoagulant activities of Warfarin.Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Betamethasone is combined with Yellow Fever Vaccine.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Betamethasone.Approved, Investigational
ZeranolThe serum concentration of Betamethasone can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Betamethasone.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Betamethasone.Withdrawn
Food Interactions
  • Take with food to reduce irritation.

References

Synthesis Reference

Fernando AHUMADA AYALA, "SKIN-CARE PREPARATIONS CONTAINING MUPIROCIN AND BETAMETHASONE DIPROPIONATE." U.S. Patent US20100063015, issued March 11, 2010.

US20100063015
General References
Not Available
External Links
Human Metabolome Database
HMDB0014586
KEGG Drug
D00244
PubChem Compound
9782
PubChem Substance
46505155
ChemSpider
9399
BindingDB
73823
ChEBI
3077
ChEMBL
CHEMBL632
Therapeutic Targets Database
DAP001043
PharmGKB
PA164754818
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Betamethasone
ATC Codes
S01BB04 — Betamethasone and mydriaticsR03BA04 — BetamethasoneS01CA05 — Betamethasone and antiinfectivesH02AB01 — BetamethasoneR01AD06 — BetamethasoneD07BC01 — Betamethasone and antisepticsC05AA05 — BetamethasoneD07CC01 — Betamethasone and antibioticsD07XC01 — BetamethasoneA07EA04 — BetamethasoneS02BA07 — BetamethasoneS03BA03 — BetamethasoneS01CB04 — BetamethasoneD07AC01 — BetamethasoneS03CA06 — Betamethasone and antiinfectivesS01BA06 — Betamethasone
AHFS Codes
  • 68:04.00 — Adrenals
  • 84:06.00 — Anti-inflammatory Agents
  • 52:08.00 — Anti-inflammatory Agents
  • 56:36.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
FDA label
Download (37.5 KB)
MSDS
Download (71.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailablePsoriasis Vulgaris1
1CompletedOtherPsoriasis1
1CompletedOtherPsoriasis Vulgaris1
1CompletedTreatmentAtopic Dermatitis (AD)1
1CompletedTreatmentPlaque Psoriasis / Psoriasis1
1CompletedTreatmentPlaque Type Psoriasis1
1CompletedTreatmentPsoriasis3
1CompletedTreatmentPsoriasis Vulgaris1
1CompletedTreatmentScalp Psoriasis1
1RecruitingOtherHealthy Volunteers1
1RecruitingTreatmentBotulinum Toxins, Type A / Plantar Fascitis1
1RecruitingTreatmentPsoriasis1
1, 2CompletedTreatmentArthritis / Psoriasis1
1, 2CompletedTreatmentPsoriasis2
1, 2TerminatedPreventionCongenital Cystic Adenomatoid Malformation (CCAM)1
1, 2Unknown StatusTreatmentCorneal Diseases / Hypermetropia / Myopia / Pterygium1
2CompletedPreventionLung Cancer Non-Small Cell Cancer (NSCLC) / Metastatic Colorectal Cancers1
2CompletedTreatmentHip Pain Etiology Unknown1
2CompletedTreatmentOpen Angle Glaucoma (OAG)1
2CompletedTreatmentOral Lichen Planus / Recurrent Aphthous Stomatitis1
2CompletedTreatmentPruritus in Patients With Atopic Dermatitis1
2CompletedTreatmentPsoriasis Vulgaris2
2Not Yet RecruitingTreatmentAchilles Tendinitis / Lateral Epicondylitis / Rotator Cuff Syndrome1
2Not Yet RecruitingTreatmentLateral Epicondylitis / Rotator Cuff Syndrome1
2RecruitingTreatmentInjuries, Ankle1
2RecruitingTreatmentOral Lichen Planus1
2Unknown StatusPreventionRespiratory Distress Syndrome, Newborn / Transient Tachypnea of the Newborn1
2Unknown StatusTreatmentLate Preterm1
2, 3RecruitingTreatmentPPROM / Respiratory Distress Syndrome In Premature Infants1
2, 3TerminatedPreventionRespiratory Distress Syndrome, Newborn1
2, 3TerminatedTreatmentBronchiolitis / Children1
3CompletedPreventionPostoperative Emesis / Prophylaxis against postoperative nausea and vomiting1
3CompletedPreventionPregnancy / Pregnancy Outcomes / Respiratory Distress1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentAtopic Dermatitis (AD)1
3CompletedTreatmentCarpal Tunnel Syndrome (CTS)1
3CompletedTreatmentCoughing / Throat Pain1
3CompletedTreatmentDermatitis, Eczematous1
3CompletedTreatmentPsoriasis1
3CompletedTreatmentPsoriasis Vulgaris3
3CompletedTreatmentRespiratory Distress Syndrome (RDS)1
3Not Yet RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
3Not Yet RecruitingTreatmentInfected Atopic Dermatitis/Eczema1
3RecruitingTreatmentNeonatal Complications1
3RecruitingTreatmentPlaque Psoriasis1
3RecruitingTreatmentScalp Psoriasis1
3TerminatedTreatmentComplications, Pregnancy1
3TerminatedTreatmentCutaneous Hypersensitivity1
3TerminatedTreatmentOral Lichen Planus1
3Unknown StatusTreatmentAllergic Rhinitis (AR)1
3Unknown StatusTreatmentAtopic Dermatitis (AD) / Dermatitis, Contact / Psoriasis / Seborrheic Dermatitis1
3WithdrawnTreatmentPremature Births / Premature Labour1
4CompletedPreventionHand Eczema1
4CompletedPreventionNeonatal Distress1
4CompletedTreatmentAlopecia Areata (AA)1
4CompletedTreatmentBack Pain / Cervical Pain1
4CompletedTreatmentOsteoarthritis (OA)1
4CompletedTreatmentPsoriasis1
4CompletedTreatmentPsoriasis Vulgaris1
4CompletedTreatmentRhinitis1
4Not Yet RecruitingPreventionChronic Migraine1
4Not Yet RecruitingTreatmentBack Pain With Radiation / Low Back Pain (LBP) / Radicular; Neuropathic, Lumbar, Lumbosacral1
4Not Yet RecruitingTreatmentTrigger Finger1
4RecruitingPreventionNeonatal Respiratory Distress1
4RecruitingTreatmentDeQuervain Tendinopathy1
4RecruitingTreatmentDeQuervain's Tenosynovitis1
4RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
4RecruitingTreatmentPain, Chronic1
4RecruitingTreatmentPlaque Psoriasis2
4RecruitingTreatmentVestibular Diseases / Vestibular Neuronitis1
4TerminatedTreatmentAtopic Dermatitis (AD) / Skin Diseases, Eczematous1
4TerminatedTreatmentPlaque Psoriasis1
4WithdrawnTreatmentPhimosis1
Not AvailableCompletedNot AvailablePharmacological Action (PA)1
Not AvailableCompletedNot AvailablePlaque Psoriasis1
Not AvailableCompletedOtherPlaque Psoriasis1
Not AvailableCompletedPreventionHyaline Membrane Disease / Transient Tachypnea1
Not AvailableCompletedTreatmentBack Pain / Cervical Pain1
Not AvailableCompletedTreatmentDiscoid Lupus Erythematosus (DLE)1
Not AvailableCompletedTreatmentIntraventricular Hemorrhage / Neonatal Mortality / Respiratory Distress Syndrome (RDS)1
Not AvailableCompletedTreatmentPsoriasis1
Not AvailableRecruitingNot AvailablePsoriasis Vulgaris1
Not AvailableRecruitingPreventionNeonatal Respiratory Distress Syndrome1
Not AvailableTerminatedTreatmentThumb Carpometacarpal Joint Osteoarthritis1
Not AvailableUnknown StatusPreventionFunctional Residual Capacity / Pulmonary Function Testing / Respiratory Compliance1
Not AvailableUnknown StatusTreatmentAutoimmune Diseases / Hepatitis C Viral Infection / Lichen Planus (LP) / Vasculitis1
Not AvailableUnknown StatusTreatmentChronic Plantar Fasciitis1
Not AvailableUnknown StatusTreatmentPolymyalgia Rheumatica1
Not AvailableWithdrawnTreatmentBursitis / Tendonitis1

Pharmacoeconomics

Manufacturers
  • Schering corp sub schering plough corp
  • Parke davis div warner lambert co
  • Parke davis pharmaceutical research div warner lambert co
  • Altana inc
  • Glenmark generics inc usa
  • Perrigo new york inc
  • Taro pharmaceuticals usa inc
  • Tolmar inc
  • Schering corp
  • Savage laboratories inc div altana inc
  • Actavis mid atlantic llc
  • E fougera div altana inc
  • Pharmaderm div altana inc
  • Teva pharmaceuticals usa inc
  • Alpharma us pharmaceuticals division
  • Taro pharmaceuticals inc
  • Teva pharmaceuticals usa
  • Watson laboratories inc
  • Connectics corp
  • Tj roaco ltd
  • Pharmafair inc
  • Stat trade inc
Packagers
  • Accra Pac Inc.
  • Actavis Group
  • Advanced Pharmaceutical Services Inc.
  • American Regent
  • A-S Medication Solutions LLC
  • C.O. Truxton Inc.
  • Clint Pharmaceutical Inc.
  • Contract Pharm
  • Crown Laboratories Inc.
  • Darby Dental Supply Co. Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • DPT Laboratories Ltd.
  • E. Fougera and Co.
  • Faithful Friends Homeopathic Inc.
  • Genesis Pharmaceutical Inc.
  • Glenmark Generics Ltd.
  • Hikma Pharmaceuticals
  • Major Pharmaceuticals
  • Martin Surgical Supply
  • Mason Distributors
  • Medisca Inc.
  • Merit Pharmaceuticals
  • Nycomed Inc.
  • Palmetto Pharmaceuticals Inc.
  • Patheon Inc.
  • Perrigo Co.
  • Pharmaforce Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Qualitest
  • Quality Care
  • Rebel Distributors Corp.
  • SAL Pharma
  • Sandoz
  • Savage Labs
  • Schering Corp.
  • Stat Rx Usa
  • Stiefel Labs
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • Tolmar Inc.
  • Warrick Pharmaceuticals Corp.
Dosage forms
FormRouteStrength
GelTopical0.025 %
KitIntra-articular; Intralesional; Intramuscular
LiquidTopical.1 %
GelTopical.1 %
SuspensionIntra-articular; Intralesional; Intramuscular
Injection, suspensionIntra-articular; Intralesional; Intramuscular
Injection, suspensionEpidural; Intramuscular; Intraspinal; Intrathecal
Injection, suspensionIntramuscular
CreamTopical.5 mg/g
CreamTopical.64 mg/g
Cream, augmentedTopical.5 mg/g
GelTopical.5 mg/g
GelTopical.64 mg/g
LotionTopical.5 mg/g
Lotion, augmentedTopical.5 mg/mL
OintmentTopical.05 mg/g
OintmentTopical.5 mg/g
Ointment, augmentedTopical.5 mg/g
LotionTopical.64 mg/mL
Injection, solutionEpidural; Intramuscular; Intraspinal; Intrathecal12 mg/mL
CreamTopical1 mg/g
CreamTopical1.2 mg/g
LotionCutaneous1 mg/mL
LotionTopical1 mg/mL
OintmentTopical1 mg/g
OintmentTopical1.2 mg/g
LotionTopical1.22 mg
CreamTopical.05 %
CreamTopical.64 mg
LotionTopical.64 mg
OintmentTopical.64 mg
PatchTopical0.1 %
Solution / dropsAuricular (otic); Ophthalmic.1 %
LiquidAuricular (otic); Ophthalmic0.1 %
TabletTopical0.1 mg
EnemaRectal5 mg
TabletOral.5 mg
Tablet, effervescentOral0.5 mg
CreamTopical.1 %
LotionTopical.1 %
OintmentTopical.1 %
OintmentTopical0.1 %
OintmentTopical0.05 %
Tablet, extended releaseOral1 mg
Injection, suspensionIntra-articular; Intralesional; Intramuscular; Soft tissue
SuspensionIntra-articular; Intrabursal; Intradermal; Intramuscular
TabletOral0.5 mg
CreamTopical
LotionTopical
Kit
LotionTopical.5 mg/mL
LiquidAuricular (otic); Ophthalmic
GelTopical
CreamTopical.05 g/100g
OintmentTopical.05 g/100g
Aerosol, foamTopical
SolutionAuricular (otic); Ophthalmic
OintmentOphthalmic
Aerosol, foamTopical0.12 %
Aerosol, foamTopical1.2 mg/g
KitEpidural; Infiltration; Intra-articular; Intralesional; Intramuscular; Topical
LotionTopical.05 %
CreamTopical0.05 %
LotionTopical0.05 %
CreamTopical0.1 %
KitEpidural; Infiltration; Intra-articular; Intralesional; Intramuscular
CreamTopical0.5 mg
LotionTopical.5 mg
OintmentTopical.5 mg
CreamTopical.5 mg
OintmentTopical.05 %
KitTopical
SprayTopical.5 mg/g
OintmentTopical
Spray, meteredTopical
SuspensionTopical
LotionTopical0.1 %
Prices
Unit descriptionCostUnit
Luxiq 0.12% Foam 100 gm Can325.17USD can
Luxiq 0.12% Foam 50 gm Can174.7USD can
Diprolene 0.05% Lotion 60ml Bottle148.19USD bottle
Diprolene 0.05% Ointment 50 gm Tube147.41USD tube
Diprolene AF 0.05% Cream 50 gm Tube147.02USD tube
Betamethasone Dipropionate Aug 0.05% Ointment 45 gm Tube118.42USD tube
Diprolene 0.05% Gel 50 gm Tube103.99USD tube
Betamethasone Dipropionate Aug 0.05% Lotion 60ml Bottle100.64USD bottle
Betamethasone Dipropionate Aug 0.05% Cream 50 gm Tube88.66USD tube
Betamethasone Dipropionate Aug 0.05% Gel 50 gm Tube88.26USD tube
Diprolene 0.05% Lotion 30ml Bottle78.79USD bottle
Betamethasone acetate powd78.03USD g
Diprolene 0.05% Ointment 15 gm Tube69.38USD tube
Diprolene AF 0.05% Cream 15 gm Tube69.38USD tube
Betamethasone Dipropionate Aug 0.05% Ointment 15 gm Tube58.83USD tube
Betamethasone sod phos powder56.61USD g
Diprolene 0.05% Gel 15 gm Tube49.99USD tube
Betamethasone dp powder48.96USD g
Betamethasone valerate powd47.89USD g
Maxivate 0.05% Cream 45 gm Tube44.99USD tube
Betamethasone Dipropionate 0.05% Lotion 60ml Bottle40.4USD bottle
Betamethasone Dipropionate Aug 0.05% Cream 15 gm Tube39.62USD tube
Betamethasone Dipropionate Aug 0.05% Gel 15 gm Tube39.46USD tube
Betamethasone Dipropionate 0.05% Ointment 45 gm Tube19.67USD tube
Betamethasone Dipropionate 0.05% Cream 45 gm Tube18.9USD tube
Betamethasone Valerate 0.1% Lotion 60ml Bottle16.99USD bottle
Betamethasone Valerate 0.1% Ointment 45 gm Tube15.87USD tube
Beta-Val 0.1% Lotion 60ml Bottle14.99USD bottle
Betamethasone Dipropionate 0.05% Ointment 15 gm Tube13.51USD tube
Betamethasone Dipropionate 0.05% Cream 15 gm Tube12.99USD tube
Betamethasone Valerate 0.1% Cream 45 gm Tube12.99USD tube
Beta-Val 0.1% Cream 45 gm Tube12.99USD tube
Betamethasone Valerate 0.1% Cream 15 gm Tube11.99USD tube
Betamethasone Valerate 0.1% Ointment 15 gm Tube11.99USD tube
Beta-Val 0.1% Cream 15 gm Tube11.99USD tube
Betnesol (5 mg/100Ml) 5 mg/enm Enema9.51USD enema
Celestone soluspan 6 mg/ml8.08USD ml
Betamethasone ac-sp 6 mg/ml vial7.68USD ml
Luxiq 0.12% foam5.01USD g
Diprolene af 0.05% cream4.19USD g
Lotrisone 1-0.05% Lotion2.89USD ml
Lotrisone cream2.71USD g
Betamethasone dp aug 0.05% crm2.17USD g
Diprolene Glycol 0.05 % Glycol Cream0.54USD g
Diprolene Glycol 0.05 % Glycol Ointment0.54USD g
Ratio-Topilene 0.05 % Glycol Cream0.54USD g
Ratio-Topilene 0.05 % Glycol Ointment0.54USD g
Diprolene Glycol 0.05 % Glycol Lotion0.49USD g
Ratio-Topilene 0.05 % Glycol Lotion0.49USD g
Prevex B 0.1 % Occlusive Cream0.4USD g
Beta-val 0.1% cream0.32USD g
Ratio-Ectosone Regular 0.1 % Lotion0.3USD g
Ratio-Ectosone Mild 0.05 % Lotion0.23USD g
Diprosone 0.05 % Ointment0.23USD g
Ratio-Topisone 0.05 % Ointment0.23USD g
Diprosone 0.05 % Cream0.21USD g
Diprosone 0.05 % Lotion0.21USD g
Ratio-Topisone 0.05 % Cream0.21USD g
Ratio-Topisone 0.05 % Lotion0.21USD g
Betamethasone va 0.1% cream0.14USD g
Betaderm Regular 0.1 % Ointment0.1USD g
Ratio-Ectosone Regular 0.1 % Cream0.1USD g
Valisone Scalp 0.1 % Lotion0.1USD g
Betaderm Regular 0.1 % Cream0.09USD g
Ratio-Ectosone Scalp 0.1 % Lotion0.09USD g
Betaderm Mild 0.05 % Ointment0.07USD g
Betaderm Mild 0.05 % Cream0.06USD g
Ratio-Ectosone Mild 0.05 % Cream0.06USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6126920No1996-03-012016-03-01Us
US7078058No1997-05-242017-05-24Us
US6753013No2000-01-272020-01-27Us
US6787529No2000-01-272020-01-27Us
US9119781No2011-06-102031-06-10Us
US9439911No2010-08-312030-08-31Us
US9433630No2010-08-312030-08-31Us
US9655907No2010-08-312030-08-31Us
US9364485No2010-08-312030-08-31Us
US9775851No2010-08-312030-08-31Us
US9877974No2010-08-312030-08-31Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)232 °CU.S. Patent 3,164,618
water solubility66.5 mg/L (at 25 °C)EPA
logP1.94HANSCH,C ET AL. (1995)
logS-3.77ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0505 mg/mLALOGPS
logP1.93ALOGPS
logP1.68ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.42ChemAxon
pKa (Strongest Basic)-3.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity102.49 m3·mol-1ChemAxon
Polarizability40.88 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.992
Blood Brain Barrier+0.9781
Caco-2 permeable+0.8304
P-glycoprotein substrateSubstrate0.7862
P-glycoprotein inhibitor INon-inhibitor0.8112
P-glycoprotein inhibitor IINon-inhibitor0.8134
Renal organic cation transporterNon-inhibitor0.7971
CYP450 2C9 substrateNon-substrate0.8733
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateSubstrate0.7315
CYP450 1A2 substrateNon-inhibitor0.938
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9247
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9169
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9399
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1482 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9558
hERG inhibition (predictor II)Inhibitor0.5091
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ab9-0239000000-6da1b4bf9567b7486622
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05i4-2930000000-bc11f96b96bcca3051a8
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00dj-3960000000-a7dc9d06200fd3114dc2

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols
show 8 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / Pregnane-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 17-hydroxysteroid / 11-hydroxysteroid / 11-beta-hydroxysteroid / 9-halo-steroid
show 23 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:3077)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Tanigawa K, Nagase H, Ohmori K, Tanaka K, Miyake H, Kiniwa M, Ikizawa K: Species-specific differences in the glucocorticoid receptor transactivation function upon binding with betamethasone-esters. Int Immunopharmacol. 2002 Jun;2(7):941-50. [PubMed:12188035]
  2. Aida K, Shi Q, Wang J, VandeBerg JL, McDonald T, Nathanielsz P, Wang XL: The effects of betamethasone (BM) on endothelial nitric oxide synthase (eNOS) expression in adult baboon femoral arterial endothelial cells. J Steroid Biochem Mol Biol. 2004 Aug;91(4-5):219-24. [PubMed:15336699]
  3. Johnstone JF, Bocking AD, Unlugedik E, Challis JR: The effects of chorioamnionitis and betamethasone on 11beta hydroxysteroid dehydrogenase types 1 and 2 and the glucocorticoid receptor in preterm human placenta. J Soc Gynecol Investig. 2005 May;12(4):238-45. [PubMed:15866114]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]

Drug created on June 13, 2005 07:24 / Updated on June 19, 2018 10:51